Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Cell Counting Global Market Report 2022: Applications of Cell Counting in Personalized Medicine Presents Opportunities - ResearchAndMarkets.com

The "Cell Counting Market Size, Share & Trends Analysis Report by Product (Instruments, Consumables & Accessories), by Application (Complete Blood Count, Stem Cell Research), by End-use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global cell counting market size is expected to reach USD 15.46 billion by 2030, according to this report., expanding at a CAGR of 8.21% from 2022 to 2030. The rising prevalence of chronic diseases such as cancer, HIV, and Alzheimer's is the high impact rendering growth driver of the industry. The increasing prevalence of these diseases has surged clinical research activities, consequently propelling the demand for cell counting instruments and consumables. Government initiatives working to promote the development of cell therapeutics, wherein cell counting plays an imperative role, are also expanding growth prospects for the market.

An increase in the number of collaborations of research institutes with various public and private entities to promote R&D has provided a significant boost to the growth. The growing number of proposed guidelines and recommendations for public and private laboratories to ensure high-quality standards and facilitate the generation of accurate results are likely to improve the adoption of instruments over the coming years. For instance, in May 2021, the International Society for Stem Cell Research updated guidelines for the development of cell-based therapy and research. The proposed guidelines focus on all stages of R&D and improve the quality of preclinical studies.

Technological advancements in these devices are also broadening growth prospects of the market. One of the promising technological advancements in differential cell counting is the ability to recognize blasts, immunoplatelet counting, detection of blasts, and reticulocyte fractions and stem cell counting with greater accuracy. The advent of CD4+ T-cell counting technology has proven to be very useful as an indicator of immune responses and has been adopted to evaluate the success or failure of Anti-retroviral Therapy (ARV). Dedicated cytometers are present in the market to perform CD4+ and CD8+ T-cell enumeration, such as the FACSCount by Becton Dickinson is based on T-cell counting technology.

The COVID-19 pandemic is anticipated to positively impact the industry growth. WBC count of the COVID-19 patient during admission is significantly correlated with the death of patients. A higher level of white blood count should be given further care in the COVID-19 treatment. The growing importance of cell count in patients suffering from COVID-19 has augmented the growth of the industry during the pandemic.

The development of enhanced informatics solutions and improved image analysis instruments such as optical or fluorescence microscopes have fueled growth prospects of this market. These instruments are being increasingly adopted in low sample throughput laboratories and settings with limited resources, which is highly prevalent in developing economies, thereby broadening the scope for growth of the industry.

On the other hand, limited availability of skilled professionals is the critical growth-restraining factor of the market. The lack of skilled professionals can be attributed to lack of training facilities and high training costs. In order to improve this scenario, industry players are required to participate in the generation of training programs for software developed by these companies and encourage healthcare professionals and researchers to operate cell counting software. Moreover, lack of standardization of these software tools also plays a key role in restricting researchers and healthcare professionals as every software differs in user interface.

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Market Definitions

Chapter 3 Executive Summary

Chapter 4 Global Cell Counting Market Variables, Trends, & Scope

Chapter 5 Cell Counting Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

Chapter 6 Cell Counting Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

Chapter 7 Cell Counting Market - Segment Analysis, by End-use, 2018 - 2030 (USD Million)

Chapter 8 Cell Counting Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7v0vpn

These press releases may also interest you

at 07:20
Baxter International Inc. , a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2022, and provided its financial guidance for full-year and first-quarter 2023. "Baxter employees worldwide are embracing...

at 07:20
Kite, a Gilead Company , today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). Results from the analysis showed a median overall survival (OS) of 26 months and...

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will...

at 07:05
AVROBIO, Inc. , a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical correction in the first pediatric Gaucher disease type 3 (GD3)...

at 07:05
Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within, today announced the closing of its previously announced acquisition of Twelve Bio...

at 07:05
Bruker Corporation today announced financial results for its fourth quarter and for the fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Results Bruker's revenues for the fourth quarter of 2022 were $708.4 million, an increase of...

News published on 6 december 2022 at 06:45 and distributed by: